Commercial teams in charge of oncology products are grappling with
rapid changes in the regulatory, clinical and commercial landscape in
which they operate. A number of these have specific implications for
oncology portfolio planning and indication launch sequencing, including:
- Scientific and technological advances are revealing tumors in different tissue types may share a similar etiology or may be vulnerable to therapeutic intervention via a common mechanism of action (MOA) or pathway.
- Precision medicine treatments that target specific biomarkers and gene mutations which may become actionable are being investigated in multiple malignancy types. Treatment paradigms in oncology are changing rapidly due to an increasing number of drug approvals, necessitating a need to strategically plan indication launches and to move rapidly toward therapeutic advances.
- Opportunities for accelerated approvals, a large number of potential indications (there are over 150 types of cancer), low generic penetration and high reimbursement levels also incentivize companies both to develop new oncology therapies and obtain additional indication approvals for existing ones.
- Multi-indication portfolio planning has become a key part of oncology drug development, and oncology drugmakers today can expect to mount a sequence of indication launches over the life cycle of their asset. As they do so, patients benefit from additional treatment options, and the research involved advances the understanding of these diseases. Yet, having multiple opportunities also tasks executives and researchers to set priorities and craft a well-defined approach to launch sequencing that is, at once, farsighted and sufficiently practical to leverage current marketplace opportunities.
This report will cover key considerations for sequencing of drug development and commercialization, outlining an approach to determining which indications should be developed first to maximize commercial opportunity and get to market faster.
Download the Report Below
